OpGen Past Earnings Performance
Past criteria checks 0/6
OpGen's earnings have been declining at an average annual rate of -6.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 9.4% per year.
Key information
-6.5%
Earnings growth rate
57.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -9.4% |
Return on equity | -314.7% |
Net Margin | -783.5% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
OpGen to raise $3.38M in direct stock offering
Sep 30OpGen's subsidiary signs R&D agreement with FIND
Sep 20Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement
Aug 31OpGen launches sequencing services for infectious diseases in US
Aug 25OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line
Aug 11OpGen reports preliminary revenue estimate for Q2 2022
Jul 08OpGen gains on insider buying
Jun 15OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates
Jun 07OpGen reports prelim Q4 & FY20 revenue
Jan 13OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia
Jan 05OpGen launches $10M private placement
Nov 24OpGen EPS misses by $0.04, beats on revenue
Nov 11OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform
Oct 28Revenue & Expenses Breakdown
How OpGen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 1 | -10 | 6 | 0 |
30 Jun 24 | 2 | -22 | 7 | 0 |
31 Mar 24 | 3 | -27 | 9 | 0 |
31 Dec 23 | 3 | -33 | 11 | 0 |
30 Sep 23 | 3 | -26 | 13 | 0 |
30 Jun 23 | 3 | -36 | 13 | 0 |
31 Mar 23 | 3 | -36 | 13 | 0 |
31 Dec 22 | 3 | -37 | 13 | 0 |
30 Sep 22 | 3 | -41 | 14 | 0 |
30 Jun 22 | 4 | -33 | 14 | 0 |
31 Mar 22 | 4 | -34 | 14 | 0 |
31 Dec 21 | 4 | -42 | 14 | 0 |
30 Sep 21 | 4 | -35 | 13 | 0 |
30 Jun 21 | 4 | -37 | 13 | 0 |
31 Mar 21 | 4 | -37 | 13 | 0 |
31 Dec 20 | 4 | -26 | 12 | 0 |
30 Sep 20 | 4 | -22 | 10 | 0 |
30 Jun 20 | 3 | -17 | 9 | 0 |
31 Mar 20 | 3 | -13 | 8 | 0 |
31 Dec 19 | 3 | -12 | 8 | 0 |
30 Sep 19 | 3 | -14 | 8 | 0 |
30 Jun 19 | 3 | -13 | 8 | 0 |
31 Mar 19 | 3 | -14 | 9 | 0 |
31 Dec 18 | 3 | -13 | 9 | 0 |
30 Sep 18 | 3 | -13 | 8 | 0 |
30 Jun 18 | 3 | -13 | 8 | 0 |
31 Mar 18 | 3 | -13 | 9 | 0 |
31 Dec 17 | 3 | -15 | 9 | 0 |
30 Sep 17 | 3 | -17 | 11 | 0 |
30 Jun 17 | 3 | -19 | 12 | 0 |
31 Mar 17 | 4 | -20 | 12 | 0 |
31 Dec 16 | 4 | -19 | 12 | 0 |
30 Sep 16 | 4 | -19 | 13 | 0 |
30 Jun 16 | 5 | -19 | 12 | 0 |
31 Mar 16 | 4 | -19 | 11 | 0 |
31 Dec 15 | 3 | -18 | 10 | 0 |
30 Sep 15 | 3 | -14 | 8 | -3 |
30 Jun 15 | 3 | -12 | 6 | 0 |
31 Mar 15 | 4 | -8 | 5 | 0 |
31 Dec 14 | 4 | -6 | 4 | 0 |
30 Sep 14 | 4 | -9 | 4 | 3 |
31 Dec 13 | 2 | -16 | 6 | 0 |
Quality Earnings: OPGN is currently unprofitable.
Growing Profit Margin: OPGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OPGN is unprofitable, and losses have increased over the past 5 years at a rate of 6.5% per year.
Accelerating Growth: Unable to compare OPGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: OPGN has a negative Return on Equity (-314.74%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 23:19 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OpGen, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Benjamin Haynor | Alliance Global Partners |
null null | Brookline Capital Markets |
Nidhi Singh | Edison Investment Research |